Patents Assigned to Leuven Research & Development VZQ
  • Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
    Patent number: 6946438
    Abstract: The present invention relates to a new means for the treatment of focal ischemic cerebral infarction (ischemic stroke). It has been found that reduction of ?2-antiplasmin leads to a significantly smaller focal cerebral infarct size. The invention therefore provides the use of compounds that reduce ?2-antiplasmin concentration or activity in vivo, for the preparation of a therapeutical composition for the treatment of focal cerebral ischemic infarction (ischemic stroke).
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: September 20, 2005
    Assignees: Leuven Research & Development VZQ
    Inventors: Nobuo Nagai, Désiré José Collen